Business Context and Reporting Period
Company: Silo Pharma, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: September 21, 2021
Event Date: September 21, 2021 to September 23, 2021
Context: The filing reports the entry into a Material Definitive Agreement regarding the sale of equity holdings in another company.
Key Financial Metrics
This filing does not contain standard financial statements (revenue, profit, cash flow, margins, debt, or liquidity) for Silo Pharma, Inc. The only specific financial metric disclosed relates to a transaction:
- Transaction Proceeds: Approximately $6.6 million from the sale of DatChat, Inc. shares.
- Asset Sold: 1,000,000 shares of DatChat, Inc. (a communications software company that recently completed its IPO).
Material Changes
The material change reported is the divestiture of a significant equity position. Between September 21 and September 23, 2021, Silo Pharma entered into Stock Purchase Agreements with an institutional purchaser to sell its entire holding of 1,000,000 shares of DatChat, Inc. This follows a previous disclosure on August 18, 2021, regarding the ownership of these shares.
Guidance, Outlook, and Risks
The filing text does not provide forward-looking guidance, management commentary on future operations, specific risk factors, or contingencies beyond the execution of the stock sale. The transaction appears to be a completed liquidity event for the DatChat investment.
Key Facts for Investor Verification
- Verify the exact closing date and final settlement amount of the $6.6 million DatChat share sale.
- Confirm the impact of this transaction on Silo Pharma's cash position and balance sheet in subsequent filings (e.g., 10-Q or 10-K).
- Review the "Form of Stock Purchase Agreement" (Exhibit 10.1) for any remaining obligations or representations made by the company.
- Check if the sale of DatChat shares was part of a broader strategy to liquidate non-core assets.